Needham Maintains Buy on Blueprint Medicines, Raises Price Target to $133
Needham Maintains Buy on Blueprint Medicines, Raises Price Target to $133
Needham維持Blueprint Medicines的買入評級，將價格目標上調至133美元。
Needham analyst Ami Fadia maintains Blueprint Medicines (NASDAQ:BPMC) with a Buy and raises the price target from $130 to $133.
Needham分析師 Ami Fadia 維持對blueprint medicines（納斯達克代碼：BPMC）的買入評級，將目標股價從130美元上調至133美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。